Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials

• Prif Awduron: Roberta Venturella (Awdur), Tomasz Rechberger (Awdur), János Zatik (Awdur), Rachel B. Wagman (Awdur), Emily Zhu (Awdur), Viatcheslav G. Rakov (Awdur), Felice Petraglia (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Objective In the 24-week, phase 3 LIBERTY 1 (L1) and LIBERTY 2 (L2) trials, relugolix combination therapy (relugolix-CT (relugolix 40 mg, estradiol 1 mg, norethisterone acetate 0.5 mg)) reduced uterine fibroid (UF)-associated symptoms. This post hoc analysis assessed safety and efficacy of relugolix...